AllSci News
Johnson & Johnson's JNJ-4804 doubles clinical remission in Phase IIb refractory Crohn's disease trial
Johnson & Johnson (NYSE: JNJ) reported Phase IIb data showing that JNJ-4804, its investigational co-antibody combining guselkumab and golimumab, produced...
Viridian's elegrobart meets primary endpoint in Phase III chronic thyroid eye disease trial
Viridian Therapeutics (Nasdaq: VRDN) reported that elegrobart met its primary endpoint in the Phase III REVEAL-2 trial in chronic thyroid eye disease, with...
Madrigal picks up Arrowhead's ARO-PNPLA3 MASH program in potential USD 1b deal
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has granted an exclusive worldwide license for ARO-PNPLA3, its Phase I-stage RNAi therapeutic targeting the PNPLA3...
Insilico's rentosertib inhalation solution receives China IND clearance for IPF
Insilico Medicine (HKEX: 3696) announced that China's Center for Drug Evaluation (CDE) has cleared an investigational new drug (IND) application for an...
Merck revises TERN-701 efficacy down, navigates mixed Welireg results, accelerates enlicitide timeline
Merck held its Q1 2026 earnings conference call on April 30, 2026, during which the company's pipeline narrative was dominated by three converging signals:...
GSK's Q1'26 Earnings Call: bepirovirsen in HBV, ADC pipeline in focus
GSK's Q1 2026 earnings conference call, held April 29, 2026, centered on three converging pipeline signals: positive Phase III data for bepirovirsen in...
Amgen's Q1'26 Earnings Call: Executives discuss MariTide Phase III program, Tavneos regulatory challenge
Amgen's AMGN Q1 2026 earnings conference call, held April 30, 2026, was dominated by three pipeline signals: an expanding Phase III program for MariTide...
Hemab Therapeutics raises USD 346.7m via Nasdaq listing to fund rare blood disorder therapies
Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) announced the closing of its initial public offering on May 4, 2026, raising approximately USD 346.7...
Satellite Bio wins FDA Rare Pediatric Disease designation for SB-101 in urea cycle disorders
Satellite Biosciences announced receipt of a Rare Pediatric Disease (RPD) designation from the FDA for SB-101, an allogeneic off-the-shelf hepatocyte cell therapy,…
Johnson & Johnson's lumateperone ranks highest in adjunctive major depressive disorder network meta-analysis
Johnson & Johnson (NYSE: JNJ) reported that lumateperone (Caplyta) ranked highest across four efficacy measures in a network meta-analysis comparing...
Cabaletta Bio raises USD 150m via share offering
Cabaletta Bio (Nasdaq: CABA), a Philadelphia-based clinical-stage cell therapy company, announced the pricing of an underwritten public offering to raise...
Cue Biopharma raises USD 30m in private placement PIPE financing
Boston-based Cue Biopharma, Inc. (Nasdaq: CUE) announced a USD 30 million PIPE financing on April 30, 2026, with proceeds directed toward advancing its...
Climb Bio raises USD 110m in private placement for immune-disease pipeline
Wellesley Hills, Massachusetts-based Climb Bio, Inc. (Nasdaq: CLYM) announced a USD 110.0 million private placement to fund continued clinical development...
Rein Therapeutics raises USD 50m in public share offering
US-based Rein Therapeutics (Nasdaq: RNTX) announced an underwritten public offering of common stock priced at USD 50 million, with proceeds designated to...
Aura Biosciences raises USD 260.3m in public offering of common stock
Aura Biosciences (Nasdaq: AURA) announced the pricing of an underwritten public offering to fund registration-enabling activities for its lead asset,...
The AllSci Brief
Systematic R&D and deal news. Daily.